<DOC>
	<DOCNO>NCT02885753</DOCNO>
	<brief_summary>Colorectal cancer 3rd common cancer France 2nd cause death cancer . Between 30 60 % patient develop limited predominant liver metastasis . Surgical resection metastasis , curative treatment immediately possible 10-15 % case . In unresectable patient , current palliative treatment base systemic chemotherapy associate targeted therapy ( anti-EGFR ( panitumumab ) , anti-VEGF ( bevacizumab ) ) . In patient population , special attention pay intensified treatment regimen order improve efficiency improve tumoral response rate , intensity response earliness correlate improve overall progression-free survival . The intra-arterial use oxaliplatin couple IV chemotherapy yield OR level 64 % patient survive one line chemotherapy IV 62 % patient progress oxaliplatin IV . In addition , HIA administration oxaliplatin limit systemic especially neurological toxicity , thanks great hepatic clearance . In conclusion , combination systemic chemotherapy , target therapy HIAC oxaliplatin show promising efficacy result associate good tolerance first line onwards . Indeed , expect Phase II recent data , control rate close 100 % , high response rate associate early maturity depth response well prolonged survival . However , date , absence randomize trial test combination , strategy sufficient evidence integrate routine practice , HIAC remain limited expert center treatment catch-up .</brief_summary>
	<brief_title>Systemic Oxaliplatin Intra-arterial Chemotherapy Combined With LV5FU2 Target Therapy First Line Treatment Metastatic Colorectal Cancer Restricted Liver</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Histologically proven colorectal adenocarcinoma hepatic metastasis ( e ) At least one measurable hepatic metastasis accord criterion RECIST v1.1 No metastatic site except lung nodule number ≤ 3 &lt; 10 mm RAS mutation status know ( determination KRAS mutation ( exon 2,3 4 ) determination NRAS mutation ( exon 2,3 4 ) ) Age ≥ 18 WHO ≤ 2 ( Appendix 4 ) No prior treatment chemotherapy except perioperative adjuvant chemotherapy discontinue 12 month Life expectancy &gt; 3 month PNN &gt; 1500/mm3 , platelet &gt; 100 000/mm3 , Hb &gt; 9 g/dLq Bilirubin &lt; 25 mmol/L , AST &lt; 5x ULN , ALT &lt; 5 x ULN , ALP &lt; 5 x ULN , TP &gt; 60 % , proteinuria 24H &lt; 1 g Creatinine clearance &gt; 50 mL/min accord MDRD formula ( Appendix 4 ) Patient affiliate social security scheme Patient information signature inform consent Contraindications specific installation KTHIA : thrombosis hepatic artery , arterial vascular anatomy may compromise secondary hepatic resection . Patient immediately eligible curative therapy ( surgical and/or percutaneous ) discussion CPR Following alteration 6 month prior inclusion : myocardial infarction , angina , severe/unstable angina , coronary artery bypass surgery , congestive heart failure NYHA class II , III IV , stroke transient ischemic attack Hypertension control medical treatment ( SBP &gt; 140 mmHg and/or DBP &gt; 90 mmHg blood pressure take accord diagram HAS ) A history abdominal fistula , gastrointestinal perforation , intraabdominal abscess active gastrointestinal bleed 6 month precede start treatment Progressive gastroduodenal ulcer , wound fracture bone Abdominal major extraabdominal surgery ( except diagnostic biopsy ) irradiation 4 week start treatment Transplant patient , HIV positive immune deficiency syndromes Any progressive pathology balance past 6 month : hepatic failure , renal failure , respiratory failure Peripheral neuropathy &gt; 1 Patient interstitial pneumonitis pulmonary fibrosis History chronic diarrhea inflammatory disease colon rectum , unresolved occlusion subocclusion symptomatic treatment History malignant pathology past 5 year except basocellular skin carcinoma consider complete remission situ cervical carcinoma , properly treat Patient already include another clinical trial experimental molecule Any know specific contraindication allergy hypersensitivity drug use study ( cf RCP Appendix 7 ) Known deficit DPD QT/QTc range &gt; 450 msec men &gt; 470 msec woman K+ &lt; LNL , Mg2+ &lt; LNL , Ca2+ &lt; LNL Lack effective contraception patient ( men and/or woman ) childbearing age , pregnant breastfeed woman , woman childbearing age pregnancy test Persons deprive liberty supervision Impossibility undergoing medical monitoring trial geographic , social psychological reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>colorectal</keyword>
	<keyword>cancer</keyword>
	<keyword>metastasis</keyword>
	<keyword>hepatic</keyword>
</DOC>